Cargando…

Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario

BACKGROUND: Currently biomarkers play an essential role in diagnosis, treatment, and management of cancer. In non-small cell lung cancer (NSCLC) determination of biomarkers such as ALK, EGFR, ROS1 or PD-L1 is mandatory for an adequate treatment decision. The aim of this study is to determine the cli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nadal, Ernest, Bautista, Dolores, Cabezón-Gutiérrez, Luis, Ortega, Ana Laura, Torres, Héctor, Carcedo, David, Ruiz de Alda, Lucía, Garcia, J. Francisco, Vieitez, Paula, Rojo, Federico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194132/ https://www.ncbi.nlm.nih.gov/pubmed/34112097 http://dx.doi.org/10.1186/s12885-021-08407-1

Ejemplares similares

Clinical and economic impact of ‘ROS1-testing’ strategy compared to a ‘no-ROS1-testing’ strategy in advanced NSCLC in Spain
por: Rojo, Federico, et al.
Publicado: (2022)

Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP)
por: Salas, Clara, et al.
Publicado: (2022)

Frequency of ALK Rearrangement by FISH Testing and its Correlation with ALK-IHC in Adenocarcinoma of Primary Lung Origin
por: Moatter, Samar, et al.
Publicado: (2018)

Examining the role of COVID-19 testing availability on intention to isolate: A Randomized hypothetical scenario
por: Zhang, Justin C., et al.
Publicado: (2022)

Estimating the economic impact of interpersonal violence in Mexico in 2021: projecting three hypothetical scenarios for 2030
por: Cervantes, Arturo, et al.
Publicado: (2023)

ALK-rearrangements and testing methods in non-small cell lung cancer: a review
por: Shackelford, Rodney E., et al.
Publicado: (2014)

Development of a novel ALK rearrangement screening test for non–small cell lung cancers
por: Chen, Yi-Lin, et al.
Publicado: (2021)

Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain
por: Majem, Margarita, et al.
Publicado: (2022)

Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors
por: Takeyasu, Yuki, et al.
Publicado: (2021)

Schadenfreude is higher in real-life situations compared to hypothetical scenarios
por: Gonzalez-Gadea, Maria Luz, et al.
Publicado: (2018)

Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment
por: Parker, David, et al.
Publicado: (2014)

Economic Analysis of Alternative Strategies for Detection of ALK Rearrangements in Non Small Cell Lung Cancer
por: Doshi, Shivang, et al.
Publicado: (2016)

Economic effects of dietary salt reduction policies for cardiovascular disease prevention in Japan: a simulation study of hypothetical scenarios
por: Ikeda, Nayu, et al.
Publicado: (2023)

Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
por: Cha, Yoon Jin, et al.
Publicado: (2016)

ALK-rearranged squamous cell carcinoma of the lung
por: Takanashi, Yusuke, et al.
Publicado: (2015)

Endometrial cancer with an EML4-ALK rearrangement
por: Craig, Jeffrey W., et al.
Publicado: (2018)

ALK‐rearranged squamous cell carcinoma of the lung
por: Meng, Qiyi, et al.
Publicado: (2021)

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
por: Yun, Mi Ran, et al.
Publicado: (2019)

Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group
por: Kim, Hyojin, et al.
Publicado: (2014)

Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets
por: Dalurzo, Mercedes L, et al.
Publicado: (2021)

Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing
por: Conde, Esther, et al.
Publicado: (2022)

The accuracy of surrogate decision makers: informed consent in hypothetical acute stroke scenarios
por: Bryant, Jessica, et al.
Publicado: (2013)

Nephrologists' likelihood of referring patients for kidney transplant based on hypothetical patient scenarios
por: Tandon, Ankita, et al.
Publicado: (2016)

Overview of ALK and ROS1 Rearranged Lung Cancer
por: Choi, Chang Min
Publicado: (2013)

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
por: Mizuta, Hayato, et al.
Publicado: (2021)

Targeting ALK Rearrangements in NSCLC: Current State of the Art
por: Peng, Ling, et al.
Publicado: (2022)

Current status and challenges of immunotherapy in ALK rearranged NSCLC
por: Qi, Rongbin, et al.
Publicado: (2022)

Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor
por: Nakajima, Masayuki, et al.
Publicado: (2016)

Pulmonary Sarcomatoid Carcinoma with ALK Rearrangement: Frequency, Clinical-Pathologic Characteristics, and Response to ALK Inhibitor()
por: Chen, Xinru, et al.
Publicado: (2017)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition
por: Urbanska, Edyta M., et al.
Publicado: (2020)

Response to ALK‐TKIs in a lung adenocarcinoma patient harboring dual DCTN1‐ALK and ALK‐CLIP4 rearrangements
por: Gao, Fangfang, et al.
Publicado: (2022)

STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells
por: Murumägi, Astrid, et al.
Publicado: (2021)

Sampling and counting genome rearrangement scenarios
por: Miklós, István, et al.
Publicado: (2015)

Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer
por: Iwama, Eiji, et al.
Publicado: (2014)

PI3Kβ inhibition enhances ALK‐inhibitor sensitivity in ALK ‐rearranged lung cancer
por: Talwelkar, Sarang S., et al.
Publicado: (2023)

But, Who Is the Victim Here? Exploring Judgments Toward Hypothetical Bidirectional Domestic Violence Scenarios
por: Hine, Benjamin, et al.
Publicado: (2020)

Stated Preferences for Attributes of a CYP2C19 Pharmacogenetic Test Among the General Population Presented with a Hypothetical Acute Coronary Syndrome Scenario
por: Bereza, Basil G, et al.
Publicado: (2020)

ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
por: Du, Xue, et al.
Publicado: (2018)

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
por: Imanishi, Naoko, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_unmlq48ntabd3tt4d8lvlf9nqa